Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07442006
PHASE4
Glycemic Variability of Combination Therapies in T2DM
Sponsor: JW Pharmaceutical
View on ClinicalTrials.gov
Summary
Glycemic Variability of Combination Therapies in T2DM
Official title: A Multicenter Study to Evaluate Efficacy and Safety
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
178
Start Date
2025-10-29
Completion Date
2027-03-31
Last Updated
2026-03-02
Healthy Volunteers
No
Conditions
Interventions
DRUG
Empagliflozin/Metformin
5/500 mg, 5/1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
DRUG
Anagliptin
100 mg, for 12 weeks (PO, BID)
DRUG
Metformin
500 mg, 1000 mg (based on prior Metformin dose), for 12 weeks (PO, BID)
DRUG
Empagliflozin/Linagliptin
10/5 mg, for 12 weeks (PO, QD)
Locations (1)
The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator
Seoul, South Korea